Neutrophils are the most abundant white blood cells and are the first recruited to inflammatory sites. Neutrophils are an important component of the tumor stroma and can exert both anti-tumoral and pro-tumoral activities, depending on their maturation and activation state. In human gliomas, the number of circulating and infiltrating neutrophils correlates with the severity of the disease, indicating a prognostic and possible pro-tumoral role for these leukocytes. In glioma preclinical models, neutrophils promote tumor growth and orchestrate the resistance to anti-angiogenic therapies. Nevertheless, recent data indicate that neutrophils can be activated to directly kill tumor cells or to orchestrate the anti-tumoral response. Here, we review current knowledge about the role of neutrophils in glioma and their possible involvement in new strategies to improve current cancer therapies.
Neutrophils in gliomas / M. Massara, P. Persico, O. Bonavita, V. Mollica Poeta, M. Locati, M. Simonelli, R. Bonecchi. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 8(2017 Oct 26), pp. 1349.1-1349.7. [10.3389/fimmu.2017.01349]
Neutrophils in gliomas
M. Massara;P. Persico;O. Bonavita;M. Simonelli;R. Bonecchi
2017
Abstract
Neutrophils are the most abundant white blood cells and are the first recruited to inflammatory sites. Neutrophils are an important component of the tumor stroma and can exert both anti-tumoral and pro-tumoral activities, depending on their maturation and activation state. In human gliomas, the number of circulating and infiltrating neutrophils correlates with the severity of the disease, indicating a prognostic and possible pro-tumoral role for these leukocytes. In glioma preclinical models, neutrophils promote tumor growth and orchestrate the resistance to anti-angiogenic therapies. Nevertheless, recent data indicate that neutrophils can be activated to directly kill tumor cells or to orchestrate the anti-tumoral response. Here, we review current knowledge about the role of neutrophils in glioma and their possible involvement in new strategies to improve current cancer therapies.File | Dimensione | Formato | |
---|---|---|---|
fimmu-08-01349.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.9 MB
Formato
Adobe PDF
|
1.9 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.